Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Asciminib

c0059da7-2021-561e-8a68-981804dafdb7 · FDA Approved · targets BCR_ABL, ABL1, ABL2_ARG

Asciminib

MeasuredReference

Asciminib has no high-confidence primary targets in the catalog. Strongest hallmark effect: evading apoptosis.

Primary targets

No high-confidence primary targets.

Top hallmarks

  • evading apoptosis650
  • tumor promoting inflammation619
  • proliferation608

Top pathways disrupted

  • pi3k akt mtor signaling1.1k
  • apoptosis1.1k
  • e2f targets1.1k

Resistance landscape — Asciminib

MeasuredReference

No variant annotations found on Asciminib's top targets.

No variant annotations on Asciminib's top targets.
Open in new tab